please write in your own words. please

1. Explain the concept of Supply Chain Management. L. From the description in the case study, describe what do you thing is J&J's Supply Chain Model (network) including suppliers, channel partners, distribution centers, customers. (You can draw their SCM diagram to include with the description). 2. What is the major problem that J&J Supply Chain is facing in the cases study? 2.1. Why this represent a security risk for the organization? M ME Reader - https://playeruuheducation.com/epub/sn 25af0repubdi(%2F6%2F328%5Bdata uuid-792bb3779444058bfce5301163%5D%2F%2F2%58data uuid-ded!) M Gmail YouTube Maps Home Impact Statement J&J's decision to use the adaptive software brings compliancy to their operation with a total investment that amounted to 70 percent less than originally estimated. Further, their innovative solution has put an infrastructure in place that will require minimal changes as they continue their direction to eventually replace the legacy WMS. Applicability As the pharmaceutical industry moves toward serialization in compliance with the federal Drug Supply Chain Security Act, J&J's unique and innovative approach offers companies in any industry an alternative to expensive software development and customization. Utilizing an adaptive software approach, J&J developed a proven solution to bring their supply chain to compliancy offering a safer and more secure drug supply across the globe. That solution could translate to any industry in need of efficiency, safety and compliancy. Case Study A Drug manufacturers around the globe are preparing for one of the most vital and comprehensive challenges ever faced by the industry. The goal is total security of the world's drug supply, not just at the point of manufacturing but throughout the supply chain and the life cycle of these drugs. In concert with governmental agencies and regulatory bodies, this new challenge involves the pharmaceutical manufacturers as well as wholesalers, distributors, retailers, and suppliers. Additionally, this challenge will require the efforts of software, technologs and equipment suppliers. It will be pervasive, and it will require a major fundamental change in the way the pharmaceutical industry thinks about manages, and moves inventory For years, the pharmaceutical industry has been dealing with issues of counterfeit and diverted drugs. Despite the considerable investment on the part of the manufacturers and the FDA a number of counterfeit products continue to make it into the Type here to search O EN